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Abstract A series of monoclonal antibodies (mAbs) specific for
the K-neurotoxin I (Aah I) from the venom of the dangerous
Androctonus australis hector scorpion were obtained using
carrier protein-coupled toxin. Competitive RIA, receptor assays
and mouse toxicity tests were performed to characterise mAbs in
terms of affinity and neutralisation. Cross-reactivity studies and
two-site ELISA results allowed some classification of mAbs into
three groups. One mAb, 9C2, was particularly interesting since it
recognised the parent toxin I with a KD of 0.15 nM and was also
reactive with toxins of the same immunological group. Its ability
to neutralise the toxic effect of the parent toxin and the venom
fraction has been investigated. This anti-Aah I mAb 9C2,
associated with anti-Aah II mAb 4C1, provides a valuable tool to
neutralise the toxicity of the venom.
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1. Introduction
Scorpion envenomation is an important health problem in
some regions in the world [1,2]. Venoms contain toxins that
act on ion channels [3,4] and that are likely to be responsible
for the noxious e¡ects observed when people are stung by
scorpions. Neutralisation of these molecules is an important
challenge and the use of monoclonal antibodies (mAbs) may
be advantageous. Recent advances in antibody engineering
methodology have enhanced the ¢eld of mAb applications
[5]. Venom from Androctonus australis hector (Aah), a North
African scorpion, contains several potent K-neurotoxins,
which are deadly to mammals. These toxins bind to receptor
site 3 on the rat sodium channel and inhibit inactivation [6^8].
Neurotoxins I, II and III (Aah I, Aah II, Aah III) are present
in approximately equal amounts in the venom (1^2%) with
slight variations depending on the geographic location of
the scorpions [9]. These toxins can be classi¢ed into two di¡er-
ent groups based on both structural and immunological prop-
erties. There is no cross-reactivity between the toxins of group
1 (Aah I and III) and group 2 (Aah II) when using speci¢c
rabbit antisera [10]. The structure-activity and structure-anti-
genicity relationships are well documented for the most potent
toxin, Aah II [11^14] and one high-a⁄nity mAb has been
obtained [15] and expressed as a single chain antibody frag-
ment (scFv) in Escherichia coli [16]. Knowledge of properties
of Aah II combined with chemical peptide synthesis led to the
design of non-toxic immunogens capable of inducing neutral-
ising antibodies which protect against Aah II challenge [17].
In the current work, mAbs against Aah I were produced to
study the e¡ectiveness of complete neutralisation of the A.
australis hector scorpion venom. We found that procedures
used to obtain anti-Aah II mAbs failed for Aah I. Aah I
was non-immunogenic in mice when injected in its native
form in sub-lethal doses. Injection of higher quantities of a
detoxi¢ed antigen or a non-toxic analogue did not improve its
immunogenicity. It was possible to elicit a series of mAbs that
recognise the native toxin in a liquid-phase immunoassay,
after coupling Aah I to di¡erent carrier proteins. Several of
these mAbs were characterised and classi¢ed into three
groups. They displayed high a⁄nity to the parent toxin and
were able to neutralise Aah I. Their cross-reactivity with ho-
mologous toxins and their neutralising properties against the
whole venom were also studied.
2. Materials and methods
2.1. Animals
BALB/c and C57BL/6 mice and Wistar rats were raised and housed
in the conventional animal facilities in our laboratory. Animal care
was in accordance with institutional guidelines.
2.2. Toxins and immunogens
Toxins Aah I, Aah II, Aah III and Aah IV were obtained from the
venom of the scorpion A. australis hector and toxin Bot I was ob-
tained from Buthus occitanus tunetanus. They were carefully puri¢ed
and characterised in the laboratory [18^20]. Non-toxic analogues,
(abu)8Aah I, (abu)8Aah II and (abu)8Aah III, were synthesised as
previously described [17]. For immunisation, Aah I was coupled to
(abu)8Aah II or BSA using 0.15% glutaraldehyde [21]. The molar
ratio for Aah I:(abu)8Aah II and Aah I:BSA was 4:1.
2.3. Immunisation
BALB/c female mice (6 weeks old) were given one subcutaneous
(s.c.) injection of 40 Wg of (abu)8Aah II-coupled Aah I or BSA-
coupled Aah I mixed with Freund’s complete adjuvant on day 0,
and then 40 Wg mixed in Freund’s incomplete adjuvant on days 15
and 30 by intraperitoneal (i.p.) injection. Ten days after the last in-
jection, mice were bled from the retro-orbital eye socket and sera were
tested for anti-Aah I activity by RIA. Mice used in fusion 1 were also
given i.p. injections of 40 Wg of (abu)8Aah II-coupled Aah I at days
70, 105 and 148. Six months later a ¢nal boost of a mixture of 80 Wg
of (abu)8Aah II-coupled Aah I and 4 Wg of Aah I in 0.9% NaCl was
given i.p. over 3 days. Mice used in fusion 2 were only given i.p. a
¢nal boost of 40 Wg of BSA-coupled Aah I on day 100 over 4 days.
2.4. Production of mAbs
MAbs were produced roughly as previously described [22]. Spleno-
cytes from immune mouse (108 cells) were fused with X63-F murine
myeloma cells (2U107) using polyethylene glycol 1500. For fusion 1,
hybrids were selected in HAT-RPMI 1640 medium containing 15%
FCS (Boehringer Ingelheim). Antibody-secreting cells were expanded
and cloned twice at limiting dilutions using mouse peritoneal macro-
phages as feeder cells. For fusion 2, cloning and selection were
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achieved using a methylcellulose-based medium (Clonacell-HY). After
10^14 days individual clones were picked and transferred to 96-well
plates. After screening by RIA, positives clones of the two fusions
were expanded and cells were grown as ascites tumours in pristane-
primed mice.
Antibodies were puri¢ed on protein A-Sepharose (Pharmacia) using
0.1 M Na citrate (pH 5.5 (IgG1), pH 4.5 (IgG2a) or pH 3 (IgG2b)) as
eluting bu¡er and dialysed in BBS. Purity was assessed by 12% SDS-
PAGE and pI 3^9 IEF gel (PhastSystem, Pharmacia). The protein
concentration of the IgG solutions was measured by UV spectropho-
tometry with A278 = 1.4 cm2/mg. Antigen-mediated ELISA was used
to determine the heavy chain isotype (Sigma ISO-2 kit).
2.5. Radiolabelling
Aah I or Aah II (0.5 nmol) was radiolabelled with iodine-125
(Amersham) by the lactoperoxidase method and puri¢ed as previously
described [23]. Fully active Aah I or Aah II with a speci¢c radio-
activity of 440 or 945 Ci/mmol, respectively, was obtained. Protein
A (1 nmol, Sigma) was radiolabelled by the lactoperoxidase method
and puri¢ed using Sephadex G25 (Pharmacia). Speci¢c radioactivity
was 200 Ci/mmol.
2.6. Immunoassays
2.6.1. RIA. The ability of each mAb to bind to [125I]Aah I was
assessed. Varying dilutions of puri¢ed IgG were mixed with [125I]Aah
I (1U10310 M) in PBS containing 0.1% BSA (¢nal volume of 150 Wl).
The mixtures were incubated for 90 min at 37‡C then overnight at
4‡C, 0.5 ml of sheep anti-mouse precipitating antibody (UCB Bio-
products, Belgium) was added. The mixtures were incubated for
30 min at 4‡C and then the immune complexes were centrifuged at
9000Ug for 10 min. Radioactivity was measured with a gamma coun-
ter (Packard Crystal II). All assays were performed in duplicate.
2.6.2. ELISA. For epitope mapping IgG from mAbs 2G3 and
9C2 were conjugated to ImmunoPure activated peroxidase (Pierce).
Microtitre plates (Maxisorb, Nunc) were coated with 100 Wl/well of
one puri¢ed mAb (10 Wg/ml) in PBS and incubated overnight at 4‡C.
Blocking solution (1% casein in PBS) was added to each well and the
plates were incubated for 1 h at 37‡C and then washed with 0.9%
NaCl containing 0.05% Tween 20 (NT). 1 Wg/ml of Aah I diluted in
PBS-T was added and incubated for 2 h at 37‡C. The plates were
washed with NT and further incubated with a peroxidase-conjugated
mAb 9C2 or 2G3. The wells were washed again with NT and peroxi-
dase substrate solution (TMB, Kirkegaard and Perry Labs, MD) was
added. After 10 min at room temperature, the reaction was stopped
by addition of 1 M phosphoric acid. Absorbance at 450 nm was
measured using an iEMS reader (LabSystems). The assays were car-
ried out in duplicate.
2.7. In vitro receptor assays
Synaptosomal fractions from adult rat brains were prepared as
previously described [24]. The protein contents were determined using
the Micro BCA protein assay reagent (Pierce). Binding assays were
performed in 140 mM choline chloride, 5.4 mM KCl, 0.8 mM MgCl2,
1.8 mM CaCl2, 25 mM HEPES and 0.2% BSA at pH 7.4. Inhibition
of binding of Aah I to its receptor was achieved using a mixture of
[125I]Aah II (1.5U10310 M) and Aah I (6U1038 M) incubated with
di¡erent dilutions of mAbs (1036^1038 M) for 90 min at 37‡C. The
rat brain synaptosomal preparation (1 mg/ml) was then added and
incubated for 30 min at 37‡C. The reaction was then stopped by
centrifugation and radioactivity in the pellet was measured using a
gamma counter (Packard Crystal II). Assays were performed in du-
plicate. [125I]Aah II was used as a reference because of its high a⁄nity
(KD = 0.4U10310M) for the common receptor of K-neurotoxins. The
concentration of Aah I used in the assay was determined by compet-
itive experiments using increasing concentrations of Aah I.
The binding of [125I]protein A-mAb complexes to Aah I bound to
synaptosomes was determined as previously described [25].
2.8. In vivo assays
The neutralising capacity of the mAbs was tested by the intracere-
broventricular (i.c.v.) or s.c. route. Aah I or venom toxic fraction, at
varying concentrations equal to or higher than the LD50, were pre-
incubated for 90 min at 37‡C and 30 min at 4‡C with an equal volume
of IgG from mAbs or from non-immune serum. Female C57BL/6
mice (groups of four) were injected i.c.v. (5 Wl) or s.c. (200 Wl). Surviv-
ing mice were recorded after 24 h.
Fig. 1. Cross-reactivity of anti-Aah I mAbs with Aah I and other homologous toxins assessed by competitive RIA. A: Typical curves obtained
with mAb 7D3. MAbs 2G3, 10A10, 10E6 and 5B5 displayed similar results. B: Cross-reactivities of mAb 9C2 with di¡erent ligands: Aah I
(F), Aah II (8), Aah III (b), Aah IV (k), Bot I (P), (abu)8Aah I (E) (abu)8Aah II (O), (abu)8Aah III (a). B and Bo represent the reactivity
measured in the presence (B) or absence (Bo) of ligand. C: Sequences of toxins from three immunological groups (review: [4]).
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3. Results
3.1. Characterisation of mAbs
Several hybridoma lines were generated by two fusions with
slightly di¡erent immunogens, immunisation schedules and
fusion protocols. Fusion 1 involved a long immunisation pro-
tocol using Aah I coupled to (abu)8Aah II. These hybridomas
were cloned twice by limiting dilution. Fusion 2 involved a
short-term immunisation protocol using Aah I coupled to
BSA, then methylcellulose medium was used to directly select
and clone the mAbs. The mAbs from the two fusions were
selected based on their capacity to recognise uncoupled native
toxin in RIA. Stabilised hybridomas were expended in BALB/
c mice and IgG were puri¢ed on protein A-Sepharose. Further
studies were performed using mAb puri¢ed IgG. Isotyping
revealed that mAbs from fusion 1 were IgG1 and IgG2b and
from fusion 2 were IgG1 and IgG2a. KD, as determined by
competitive RIA, ranged from 0.15 to 3 nM, showing a high
a⁄nity of all mAbs for the native toxin (Fig. 1, Table 1).
3.2. Cross-reactivity
The possible cross-reactivity of anti-Aah I mAbs with Aah
III, the toxin from the same scorpion venom that is the most
similar to Aah I (79% sequence identity) was also investigated
by RIA (Fig. 1). Only mAb 9C2 from fusion 2, which dis-
played the highest a⁄nity for Aah I, recognised Aah III, with
a KD of 1.5 nM.
K-Neurotoxins acting on mammals have been classi¢ed into
four groups on the basis of primary structure and immuno-
logical criteria [3,10]. The study of cross-reactivity of mAb
9C2 was thus continued by testing one or two toxins from
each group: Aah III and Aah IV for group 1, Aah II for
group 2 and Bot I for group 3 (Fig. 1). MAb 9C2 showed
good immunoreactivity to the other toxins of group 1. KD
values were: 0.15 nM for Aah I, 1.5 nM for Aah III and
24 nM for Aah IV (group 1). Low reactivity was observed
for toxins from group 3 (Bot I). No cross reactivity was de-
tectable for toxins from group 2.
MAbs were also assayed in a liquid-phase RIA against the
analogues of the three main toxins of the venom to determine
whether the binding of mAbs to the toxins was conformation-
dependent. These analogues mimic the entire sequences of
toxins I, II and III but with K-aminobutyric acid instead
of cysteinyl bridges. The synthetic molecules, (abu)8Aah I,
(abu)8Aah II or (abu)8Aah III, were thus devoid of their
four disulphide groups. No reactivity was observed when test-
ing these analogues (Fig. 1).
3.3. Epitope mapping
Sandwich-type ELISA and peroxidase-labelled mAbs 9C2
and 2G3 were used to establish if two mAbs could bind the
Aah I toxin at the same time. Only mAbs 2G3 and 9C2 were
able to bind Aah I simultaneously. Similar results were ob-
tained when mAb 2G3 was plate-coated and mAb 9C2 per-
oxidase-labelled or when mAb 9C2 was plate-coated and mAb
2G3 peroxidase-labelled. The speci¢city of mAbs was as ex-
pected since coated 2G3 or labelled 2G3 could not bind Aah
III. Polyclonal anti-Aah I or anti-Aah III IgG was used as a
positive controls. The other mAbs could not bind Aah I si-
multaneously (data not shown).
3.4. Inhibitory e¡ect of mAbs on binding of the toxin to its rat
brain synaptosome receptor
The lethal e¡ect of the scorpion venom is mainly due to the
binding of K-neurotoxins to a common site on voltage-de-
pendent sodium channels [6]. Aah II was used as a reference
for the K-neurotoxin binding activity because of its high af-
¢nity for the channel. Speci¢c binding of [125I]Aah II was
inhibited by Aah II (IC50 = 0.2 nM) or Aah I (IC50 = 4.5
nM). A competitive test, using both [125I]Aah II and Aah I,
Table 1
Main characteristics of anti-Aah I monoclonal antibodies
Antigen Clone KDU1039a Isotype pIc
Aah I Aah III
Aah I-(abu)8Aah II (fusion 1) 10A10 0.90 b IgG1 7.2
7D3 1.20 b IgG2b 7.8
2G3 1.80 b IgG2b 7.2/6.8
5B5 2.40 b IgG1
10E6 3.00 b IgG2b 7.7^7.5
Aah I-BSA (fusion 2) 9C2 0.15 1.50 IgG2a 7.6/7.4/7.2
aKD was calculated as in [15,31] using the formula KD = 3/8[I3T], T = [125I]Aah I = 1U10310 M, I = K0:5 determined from competitive RIA
curves.
bNo competition was observed at the highest concentration tested (5U1036 M).
cpI was determined in pI 5^9 IEF gel (Phast System, Pharmacia).
Fig. 2. Aah I neutralising capacity of anti-Aah I mAbs. Binding of
Aah I (6.3U1038 M) to rat brain synaptosomes, in the presence of
[125I]Aah II (1.5U10310 M), was inhibited by preincubation with
various concentrations of IgG from mAbs. Anti-Aah I mAbs inhib-
ited the competitive binding between Aah I and [125I]Aah II at the
common receptor. B and Bo represent the reactivity measured in
the presence (B) or absence (Bo) of mAb 9C2 (F), 2G3 (b), 10A10
(a), 10E6 (8), 7D3 (E) and 5B5 (P). BALB/c preimmune IgG was
used as a control (X).
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was performed in order to quantify the inhibitory e¡ect of
anti-Aah I mAbs on the binding of Aah I to the brain recep-
tor. Aah I, at a concentration which inhibited about 60% of
the binding of [125I]Aah II to its receptor, was incubated with
increasing amounts of puri¢ed IgG from anti-Aah I mAbs.
[125I]Aah II and synaptosomal preparation were then added.
All anti-Aah I mAbs tested were able to restore complete
binding of [125I]Aah II to the receptor whereas IgG from
non-immune mice failed to do so (Fig. 2).
The ability of mAbs 2G3 and 9C2 to bind Aah I when the
toxin was already interacting with its receptor was also tested.
Aah I (1036 M) was incubated with synaptosomal prepara-
tion, then [125I]protein A-mAb complexes were added. Only
mAb 2G3 exhibited speci¢c binding to Aah I bound to syn-
aptosomes (data not shown).
3.5. Neutralising e¡ect of mAbs on the toxicity of Aah I and
Aah venom
The toxicity of Aah I was measured in C57BL/6 mice by
i.c.v. injection. The neutralising e¡ect of mAbs was evaluated
by preincubating various amounts of Aah I with puri¢ed IgG
from each mAb and injecting the mixture i.c.v. into mice (four
mice per Aah I concentration). The controls were performed
in the same way but the mAb were replaced by IgG from non-
immune mouse serum at the same concentration (3.2 mg/ml).
In the presence of mAb 9C2, 50% of the mice injected sur-
vived an injection of 5 LD50 whereas all the control mice died
(one LD50 = 12 ng of Aah I/mouse). The protective capacity of
mAb 9C2 was 1500 LD50 per mg of puri¢ed IgG from ascitic
£uid (molar ratio toxin:IgG, 0.4:1) (data not shown).
Since mAb 9C2 recognised Aah I and Aah III, its capacity
to neutralise the Aah venom was also evaluated and com-
pared with that of anti-Aah II mAb 4C1 [15]. The synergistic
e¡ect of the two mAbs was also investigated. For this set of
experiments injections were performed by the s.c. route. In-
creasing amounts of Aah venom fraction (one LD50 = 9 Wg of
venom/mouse) were preincubated with mAb 9C2, mAb 4C1
or with a mixture of the two mAbs, as described in Table 2,
then injected s.c. into mice. 1 mg of mAb 9C2 neutralised 45
LD50 of venom, 1 mg of mAb 4C1 neutralised 40 LD50 of
venom and 1 mg of the mixture of mAbs 9C2 and 4C1 neu-
tralised 71 LD50 of venom (Table 2). Thus, for an equal
amount of total IgG the mixture of mAbs provides the highest
venom neutralisation capacity. Furthermore, when the molar
ratio 9C2/4C1 was changed, the lowest neutralisation capacity
was achieved for ratios 1/4 or 4/1 (Table 2).
4. Discussion
Aah I and Aah II are present in relatively equal amounts in
A. australis hector venom [9] and are likely to be responsible
for the lethal e¡ect of scorpion stings. Puri¢ed toxins can
induce polyclonal antibodies in rabbits but these sera do not
cross-react [10]. In order to better understand the mechanisms
of neutralisation of the toxins, production of speci¢c mAbs
was undertaken. Using low doses of Aah II or its non-toxic
analogue (abu)8Aah II, it has been possible to obtain Aah II-
speci¢c mAbs [15,26]. However, the immune response induced
by the toxin Aah I or its analogue (abu)8Aah I was not su⁄-
cient to produce antibodies. This was only achieved after cou-
pling the toxin to a carrier protein. Fusion 1 involved a long
immunisation protocol, using Aah I coupled to (abu)8Aah II.
The mAbs obtained were IgG2b and IgG1, with a KD for Aah
I ranging from 0.6 to 1.5 nM. These mAbs were all strictly
speci¢c for Aah I. Fusion 2 was performed with a short im-
munisation protocol using Aah I coupled to BSA. The mAbs
produced were IgG2a (high a⁄nity) or IgG1 (low a⁄nity). The
mAb which displayed the highest a⁄nity for Aah I, mAb 9C2
(KD = 0.15 nM) was obtained from fusion 2. All these anti-
Aah I mAbs failed to recognise the non-structured analogue
of toxin I (abu8Aah I). This result suggests that immunoreac-
tivity of the mAbs is probably dependent on the native con-
formation of the antigen. This is already the case for the anti-
Aah II mAb 4C1 (KD = 0.8 nM) [15] which was suggested to
be directed against a discontinuous epitope rather than a lin-
ear one [27].
RIA competitive experiments were performed using various
homologous toxins. All mAbs from fusion 1 (2G3, 10A10,
10E6, 7D3 and 5B5) were strictly speci¢c for Aah I (Fig.
1A). MAb 9C2 from fusion 2 also recognised toxins from
the same structural and immunological group (Fig. 1B,C),
Aah III (KD = 1.5 nM) and Aah IV (KD = 24 nM), which
have 79 and 78% sequence identity with Aah I, respectively.
However, the a⁄nity of mAb 9C2 for Aah IV was 11 times
less than for Aah III. This di¡erence in immunoreactivity can
be explained by examining the toxin sequences. A previous
Table 2
Neutralisation of the Aah venom fraction by varying mixtures of mAbs anti-Aah I, 9C2 and/or anti-Aah II, 4C1
mAb 9C2 (Wg) mAb 4C1 (Wg) Aah venom (LD50 Surviving mice
9C2 44 0 2 2/2
96 0 4 0/2
4C1 0 50 2 2/2
0 75 4 0/2
9C2+4C1 44 50 4 2/2
44 50 6 2/2
66 75 8 2/2
66 75 10 2/2
9C2+4C1 0 75 4 0/4
16 62 4 3/4
32 50 4 4/4
48 38 4 4/4
64 25 4 4/4
80 12 4 4/4
96 0 4 0/4
Aah venom fraction was incubated with mAb 9C2 or mAb 4C1 or a mixture of mAb 9C2 and mAb 4C1 for 30 min at 37‡C and then injected
s.c. into C57BL/6 mice.
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study has shown that three residues found in Aah I and Aah
III but not in Aah IV, namely V17Y, D51E and K61D, are
very important for determining biological function and ex-
plaining the di¡erences in toxicity between Aah I, Aah III
and Aah IV [20]. Furthermore, this study suggested that the
change of the doublet RK (Aah I) or YK (Aah III) at posi-
tions 60^61 to DD (Aah IV) is signi¢cant since changing the
charge may a¡ect the biological properties of the toxin.
Chemical modi¢cation of R60 or Y60 was also shown to
dramatically decrease the functional properties of the Aah I
or Aah III toxins respectively [12,13]. It is possible that one
(or more) of these three residues (V17, D51, K61) is part of
the epitope on Aah I recognised by mAb 9C2. Since mAb 9C2
decreased the toxicity of Aah I and the venom (see below),
K61 is likely to be involved. However, exact determination of
the conformational epitope of 9C2 requires further investiga-
tion [28,29]. In addition, mAb 9C2 showed low recognition of
Bot I from group 3 which shares 57% sequence identity with
Aah I (KD could not be determined but was higher than 250
nM), but no cross-reactivity was observed with Aah II (44%
sequence identity) from group 2.
A competition method (ELISA sandwich) was used to es-
tablish whether several mAbs could bind to the antigen simul-
taneously. Only mAb 2G3 and mAb 9C2 could bind to Aah I
at the same time. Furthermore, mAbs 2G3 and 9C2 competed
with all other mAbs for antigen binding. These results allowed
the classi¢cation of the mAbs into three groups. MAb 2G3
and mAb 9C2 were in two di¡erent groups and their epitopes
did not overlap each other, but they did overlap with epitopes
of mAbs from the third group (10A10, 10E6, 7D3, 5B5). In
addition, only mAb 2G3 was able to bind Aah I already
interacting with its receptor on rat brain synaptosomes.
All mAbs were able to inhibit the binding of Aah I to its
receptor on rat brain synaptosomes with varying e⁄cacy: 9C2
or 7D3s 10A10 or 5B5s 10E6 or 2G3. As already suggested
for anti-Aah II mAb 4C1 [15], one possible mechanism by
which antibodies could neutralise the toxin likely arises from
the close location of the antigenic and pharmacological sites.
Binding of a mAb on the toxin in a region more or less close
to the pharmacological site could prevent the simultaneous
binding of the toxin to synaptosomes by totally or partially
masking this site. MAbs 9C2 and 2G3 may bind the toxin at
the same time as their binding sites are probably completely
independent and located in di¡erent regions of the molecule.
MAb 2G3 was shown to bind to Aah I bound to its receptor.
The mAb 2G3 site must then not overlap with the pharmaco-
logical site on Aah I. However, mAb 2G3 was also shown to
inhibit the binding of Aah I to its receptor, although with a
lower e⁄cacy than mAb 9C2. The mAb 2G3 site may be more
distal than the mAb 9C2 site from the pharmacological site,
thus having a smaller steric hindrance.
The potency of mAb 9C2 to neutralise Aah I toxin or
venom was assessed using mouse strain C57BL/6. The neu-
tralising capacity of mAb 9C2 was 1500 LD50 (18 Wg) of Aah
I per mg of puri¢ed IgG when injected i.c.v. (one LD50 = 12
ng of Aah I/mouse). This result is comparable to that for anti-
Aah II mAb 4C1 [15] whose neutralising capacity was at least
32 000 LD50 (16 Wg) of Aah II per mg of puri¢ed IgG in the
same conditions (one LD50 = 0.5 ng of Aah II/mouse). To test
the capacity of the mAb to neutralise the venom toxic fraction
we chose the s.c. route (one LD50 = 9 Wg/mouse). Equal
amounts of venom were neutralised by anti-Aah I mAb 9C2
as by anti-Aah II mAb 4C1 (40 LD50 of venom by 1 mg of
puri¢ed IgG). This capacity was doubled when 1 mg of the
mixture of mAbs 9C2 and 4C1 was used (71 LD50 of venom
per mg of puri¢ed IgG). The appropriate dose of commercial
polyclonal antivenom is usually calculated as su⁄cient to neu-
tralise 50^100 LD50 [30]. This work shows that it is possible to
neutralise e⁄ciently the venom toxicity by using two highly
speci¢c mAbs directed against one toxin in each immunolog-
ical group.
A series of anti-Aah I mAbs have been produced and par-
tially characterised with respect to a⁄nity, neutralisation
properties and epitope mapping. The complete description
of the functional epitopes requires further protein engineering
or chemical modi¢cation of the toxin. These mAbs, presented
as IgG, Fabs or scFv, should be a good tool for neutralisation
and pharmacokinetic studies of envenomation.
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